Iron Leaf Capital Corp IRON 深 滬
已收盤 10-17 16:00:00 美东时间
89.94
+15.580
+20.95%
華盛通- 最 高95.95
- 今 開85.50
- 成交量 225.56万股
- 最 低 83.88
- 昨 收 74.36
- 總市值 31.27亿
- 52周最高 95.95
- 市盈率 靜 --
- 換手率 6.49%
- 52周最低 30.82
- 委 比 -48.80%
- 總股本 3476.56万
- 歷史最高 190.85
- 量 比 6.33
- 振 幅 16.23%
- 歷史最低 11.60
- 每 手 1
- 風險率 11.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 乘上AI东风！“储能概念”集体飙涨，Fluence周涨40%，Bloom Energy涨超28%
乘上AI东风！“储能概念”集体飙涨，Fluence周涨40%，Bloom Energy涨超28%；英伟达供应商纳微半导体股价周涨78%>>
10-18 15:02
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
Disc Medicine will present Phase 1b clinical data for DISC-0974 at the 2025 ASN Kidney Week in Houston, November 6-9. The study evaluates DISC-0974 in NDD-CKD patients with anemia, assessing safety, tolerability, and pharmacokinetics. The abstract is available on the conference website, with new data to be shared during the presentation.
10-17 13:00
Disc Medicine Receives FDA Commissioner's National Priority Voucher For Bitopertin in Erythropoietic Protoporphyria; Disc Is Seeking Accelerated Approval Of Bitopertin For Patients Aged 12 Years And Older With EPP; The CNPV Program Is Designed To Reduce The Drug Application Review Process To 1-2 Months
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
10-17 05:39
小鹏汽车公布人形机器人姿势生成专利 可生成更多动作
（来源：CNMO科技） 【CNMO科技消息】10月10日，广州小鹏汽车科技有限公司申请的“人形机器人的姿势生成方法、装置、机器人、介质及产品”专利公布。...
10-10 11:58
Disc Medicine Board Member Mona Ashiya Resigns
The latest update is out from Disc Medicine ( ($IRON) ). On October 3, 2025, Mo...
10-07 04:50
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
<p>Disc Medicine has submitted a New Drug Application (NDA) for bitopertin to treat erythropoietic protoporphyria (EPP) in patients aged 12 and older. The company seeks accelerated approval and priority review, which could reduce the FDA’s review period from 10 months to six months. Bitopertin has shown significant reductions in protoporphyrin IX (PPIX) and improvements in symptoms and quality of life in clinical trials. Disc is also conducting l...
09-30 12:30
中国品牌渐次站稳欧洲车市
来源：国际商报 本报记者 刘叶琳 在日前举行的2025年德国国际汽车及智慧出行博览会（慕尼黑国际车展）上，来自中国的多家汽车品牌以创新的技术、独特的设计、前瞻...
09-19 13:58
外媒：小鹏汽车在德国慕尼黑设立新研发中心 进一步拓展欧洲市场布局
来源：环球网 【环球网科技综合报道】9月9日，据海外科技媒体electric-vehicles报道，小鹏汽车成为又一家在德国设立欧洲研发中心的中国汽车制造商...
09-09 10:45
小鹏汽车“出海”再提速：MONA明年征战海外
来源：环球网 【环球网科技综合报道】9月9日消息，在慕尼黑IAA Mobility车展期间，小鹏汽车首席执行官何小鹏在接受CNBC采访时透露，公司计划明年将面...
09-09 10:06
